Checkpoint blockade in esophagogastric cancer Journal Article
| Authors: | Cohen, N. A.; Strong, V. E.; Janjigian, Y. Y. |
| Article Title: | Checkpoint blockade in esophagogastric cancer |
| Abstract: | There are few effective treatment options for metastatic esophagogastric adenocarcinomas after progression on second-line chemotherapy. Immune checkpoint blockade therapy is a promising treatment strategy for selected advanced esophagogastric cancer, and the PD-1 inhibitor pembrolizumab has recently been approved for metastatic or recurrent gastric or gastroesophageal junction cancer that has progressed beyond second-line systemic therapy. We review the current data supporting immune checkpoint blockade therapy in advanced esophagogastric adenocarcinoma. © 2018 Wiley Periodicals, Inc. |
| Keywords: | protein expression; treatment response; review; advanced cancer; drug efficacy; antineoplastic agent; adenocarcinoma; cancer immunotherapy; randomized controlled trials as topic; pathology; monoclonal antibody; immunology; antibodies, monoclonal; immunotherapy; stomach cancer; cytotoxic t lymphocyte antigen 4; esophagus cancer; stomach neoplasms; gastroesophageal; stomach tumor; pd-1; esophagogastric junction; programmed death 1 ligand 1; programmed death 1 receptor; randomized controlled trial (topic); gastric; gastroesophageal junction; ctla-4 antigen; nivolumab; humans; human; priority journal; checkpoint inhibitor; antagonists and inhibitors; pdcd1 protein, human; programmed cell death 1 receptor; cd274 protein, human; b7-h1 antigen; ctla4 protein, human |
| Journal Title: | Journal of Surgical Oncology |
| Volume: | 118 |
| Issue: | 1 |
| ISSN: | 0022-4790 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2018-07-01 |
| Start Page: | 77 |
| End Page: | 85 |
| Language: | English |
| DOI: | 10.1002/jso.25116 |
| PUBMED: | 29878357 |
| PROVIDER: | scopus |
| PMCID: | PMC7891842 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 October 2018 -- Source: Scopus |
Altmetric
Citation Impact
Related MSK Work